Frontlight ResearchEarly access
Taking people in NorwayPhase 1
Long-term study of RAY121 in adults with several immune-related diseases
Tests RAY121 over a longer time in adults with immune-related diseases.
Key facts
- Who runs it
- Chugai Pharmaceutical Co. Ltd.
- Where
- Graalum, Kristiansand S, and Stavanger, NorwaySee the 3 sitesAlso in 13 other countries, 34 sites
- Trial code
- Registry title
- Phase IB open label, long-term, extension basket trial of RAY121 to inhibit classical complement pathway in immunological diseases (RAINBOW-LTE trial)
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 78 people, planned
- Started
- 28 Mar 2025
- Expected to end
- 28 Dec 2026
- Type of study
- Interventional
- Record updated
- 2 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with certain immune diseases to keep taking RAY121 in a long-term extension study. The diseases are antiphospholipid syndrome, dermatomyositis, bullous pemphigoid, Behçet’s syndrome, immune-mediated necrotizing myopathy or immune thrombocytopenia.
- Age
- 18 Years and older
- Sex
- All sexes can join
Main reasons for not taking part
- Healthy volunteers cannot join
Where in Norway
Also in 13 other countries, 34 sites
- Sykehuset Oestfold HF KalnesGraalum, NorwayTaking people
- Sorlandet Sykehus HFKristiansand S, NorwayTaking people
- Helse Stavanger HFStavanger, NorwayTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Plain-language title
- Long-term study of RAY121 in adults with several immune-related diseasesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 2 November 2026